Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Experiences during the COVID-19 Pandemic among People with Inflammatory Arthritis: "Reopening of Society Is Harder than Lock-Down"-A Qualitative Interview Study

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Lund, Lene Dahl ; Løwe, Mette Margrethe ; Hendricks, Oliver ; Schreiber, Karen ; Glintborg, Bente ; Petersen, Randi ; Plischke, Christiane ; Fick, Willy ; Primdahl, Jette. / Experiences during the COVID-19 Pandemic among People with Inflammatory Arthritis: "Reopening of Society Is Harder than Lock-Down"-A Qualitative Interview Study. I: Vaccines. 2022 ; Bind 10, Nr. 7.

Bibtex

@article{f3a1b5e683584a68b2bdfdbba4a59771,
title = "Experiences during the COVID-19 Pandemic among People with Inflammatory Arthritis: {"}Reopening of Society Is Harder than Lock-Down{"}-A Qualitative Interview Study",
abstract = "People with inflammatory arthritis (IA) treated with immunosuppressive disease-modifying anti-rheumatic drugs (DMARDs) were initially considered to have an increased risk of severe illness from the SARS-CoV-2 virus compared to the general population. The aim of this study was to explore how people with IA experienced restrictions during the pandemic and the possible impact of vaccination on their protection against COVID-19 and their everyday lives. Nineteen people with IA were interviewed in May-August 2021; shortly thereafter they were enrolled in the Danish national COVID-19 vaccination programme. Concurrently, society gradually reopened after a national complete lockdown. The analysis was inspired by inductive qualitative content analysis. Participants expressed a lack of targeted information on the specific risk associated with IA if they contracted COVID-19. They had to define their own level of daily-life restrictions to protect themselves and their families. They were impacted by inconsistent announcements by the authorities, and some expressed concerns regarding the potential influence of DMARDs on vaccine effectiveness. A societal spirit of being {"}in this together{"} emerged through the lockdown, and some were concerned that the reduced level of restrictions in the reopened society would put them at higher risk of a COVID-19 infection and force them to continue self-isolating.",
author = "Lund, {Lene Dahl} and L{\o}we, {Mette Margrethe} and Oliver Hendricks and Karen Schreiber and Bente Glintborg and Randi Petersen and Christiane Plischke and Willy Fick and Jette Primdahl",
year = "2022",
month = jun,
day = "21",
doi = "10.3390/vaccines10070982",
language = "English",
volume = "10",
journal = "Vaccines",
issn = "1554-8600",
publisher = "Landes Bioscience",
number = "7",

}

RIS

TY - JOUR

T1 - Experiences during the COVID-19 Pandemic among People with Inflammatory Arthritis: "Reopening of Society Is Harder than Lock-Down"-A Qualitative Interview Study

AU - Lund, Lene Dahl

AU - Løwe, Mette Margrethe

AU - Hendricks, Oliver

AU - Schreiber, Karen

AU - Glintborg, Bente

AU - Petersen, Randi

AU - Plischke, Christiane

AU - Fick, Willy

AU - Primdahl, Jette

PY - 2022/6/21

Y1 - 2022/6/21

N2 - People with inflammatory arthritis (IA) treated with immunosuppressive disease-modifying anti-rheumatic drugs (DMARDs) were initially considered to have an increased risk of severe illness from the SARS-CoV-2 virus compared to the general population. The aim of this study was to explore how people with IA experienced restrictions during the pandemic and the possible impact of vaccination on their protection against COVID-19 and their everyday lives. Nineteen people with IA were interviewed in May-August 2021; shortly thereafter they were enrolled in the Danish national COVID-19 vaccination programme. Concurrently, society gradually reopened after a national complete lockdown. The analysis was inspired by inductive qualitative content analysis. Participants expressed a lack of targeted information on the specific risk associated with IA if they contracted COVID-19. They had to define their own level of daily-life restrictions to protect themselves and their families. They were impacted by inconsistent announcements by the authorities, and some expressed concerns regarding the potential influence of DMARDs on vaccine effectiveness. A societal spirit of being "in this together" emerged through the lockdown, and some were concerned that the reduced level of restrictions in the reopened society would put them at higher risk of a COVID-19 infection and force them to continue self-isolating.

AB - People with inflammatory arthritis (IA) treated with immunosuppressive disease-modifying anti-rheumatic drugs (DMARDs) were initially considered to have an increased risk of severe illness from the SARS-CoV-2 virus compared to the general population. The aim of this study was to explore how people with IA experienced restrictions during the pandemic and the possible impact of vaccination on their protection against COVID-19 and their everyday lives. Nineteen people with IA were interviewed in May-August 2021; shortly thereafter they were enrolled in the Danish national COVID-19 vaccination programme. Concurrently, society gradually reopened after a national complete lockdown. The analysis was inspired by inductive qualitative content analysis. Participants expressed a lack of targeted information on the specific risk associated with IA if they contracted COVID-19. They had to define their own level of daily-life restrictions to protect themselves and their families. They were impacted by inconsistent announcements by the authorities, and some expressed concerns regarding the potential influence of DMARDs on vaccine effectiveness. A societal spirit of being "in this together" emerged through the lockdown, and some were concerned that the reduced level of restrictions in the reopened society would put them at higher risk of a COVID-19 infection and force them to continue self-isolating.

UR - http://www.scopus.com/inward/record.url?scp=85133003658&partnerID=8YFLogxK

U2 - 10.3390/vaccines10070982

DO - 10.3390/vaccines10070982

M3 - Journal article

C2 - 35891146

VL - 10

JO - Vaccines

JF - Vaccines

SN - 1554-8600

IS - 7

M1 - 982

ER -

ID: 79928602